02633 JACOBSON PHARMAWatchlist
About JACOBSON PHARMA Company
The Group is a leading pharmaceutical company in Hong Kong, engaged in vertically integrated R&D, production, sales and distribution of generic drugs, specialty drugs and branded healthcare products. As a major generic drug supplier in Hong Kong, the Group has the broadest sales and distribution coverage, covering Hong Kong's public and private market sectors, and is actively expanding into strategic markets in Asia. The Group has a rich product portfolio and is in a leading position in the market in various treatment categories. It currently operates 10 licensed production facilities for generic drugs in Hong Kong. As far as branded Chinese medicines are concerned, the Group also operates two GMP certified production facilities located in Hong Kong under its branded healthcare products subsidiary. The Group invests heavily in its commercial infrastructure and manages its own warehousing, logistics, supervision, quality control, and sales and marketing operations. Our integrated warehousing facility, supported by the SAP system, is located at the transportation hub of Hong Kong to help ensure that logistics solutions are provided to customers with a high level of supply chain efficiency and flexibility.
JACOBSON PHARMA To Go Ex-Dividend On December 18th, 2023 With 0.025 HKD Dividend Per Share
November 24th - $JACOBSON PHARMA(02633.HK)$ is trading ex-dividend on December 18th, 2023. Shareholders of record on December 19th, 2023 will receive 0.025 HKD dividend per share on January 10th,
Jacobson Pharma Reports 42% Fiscal H1 Profit Growth; Shares Rise
Jacobson Pharma (HKG:2633) said total profit jumped some 42% in the six months through September 2023 to about HK$177.9 million, from an adjusted HK$125.3 million in the year-ago period. Basic earning
JACOBSON PHARMA: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023